Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-03
2006-10-03
Tate, Christopher (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S018700, C530S327000, C530S328000
Reexamination Certificate
active
07115574
ABSTRACT:
The invention includes a composition and method of treatment of sinusitis. A preferred embodiment of the invention is a composition for treatment of sinusitis comprising a therapeutically effective amount of one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV (SEQ ID NO:1), HFRWGKPV (SEQ ID NO:2), and SYSMEHFRWGKPV (SEQ ID NO:3) used in combination with a therapeutically effective amount of an antihistamine/decongestant, corticosteroid, fungicide and/or antibiotic.In yet another embodiment of the invention, one or one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV (SEQ ID NO:1), HFRWGKPV (SEQ ID NO:2), and SYSMEHFRWGKPV (SEQ ID NO:3), which may or may not be in combination with therapeutically effective amounts of antibiotics, corticosteroids and/or antihistamine/decongestants, are topically or systemically applied to treat sinusitis.
REFERENCES:
patent: 5028592 (1991-07-01), Lipton
patent: 5157023 (1992-10-01), Lipton
patent: 5739111 (1998-04-01), Mahe
patent: 6001812 (1999-12-01), Mahe
patent: 0972 522 (2000-01-01), None
patent: 2784028 (2000-04-01), None
patent: WO 93/01211 (1993-01-01), None
patent: WO/97/10838 (1997-03-01), None
patent: WO/99/58101 (1999-11-01), None
patent: PCT/US00/07846 (2000-03-01), None
patent: WO00/42856 (2000-07-01), None
U.S. Appl. No. 09/957,765, filed Sep. 21, 2000, Catania et al.
U.S. Appl. No. 09/533,341, filed Mar. 23, 2000, Catania et al.
U.S. Appl. No. 09/535,066, filed Mar. 23, 2000, Lipton.
U.S. Appl. No. 60/200,287, Lipton, filed Apr. 28, 2000.
U.S. Appl. No. 09/774,282, filed Apr. 1996, Mahe.
Airaghi, L., et. al., “Elevated concentrations of plasma α-MSH are associated with reduced disease progression in HIV-infected patients,” J. Lab. Clin. Med. 133(3) 309-315 (1999).
Airaghi L, Lettino M, Manfredi MG, Lipton JM, Catania A. Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy. Am. Heart J. 130: 204-211, 1995.
Airaghi L. Garofalo L. Cutuli MG. Delgado R. Carlin A. Demitri MT. Badalamenti S. Graziani G. Lipton JM. Catania A. Plasma concentrations of α-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis. Nephrology Dialysis Transplantation 15:1212-1216, 2000.
Baker, M., et al., “The Relationship between Interleukin-6 and Herpes Simplex Virus Type-1: Implications for Behavior and Immunopathology,”Brain Behav. Immun. 13(3):201-11 (1999).
Baker, et al., “Principles of Ambulatory Medicine,”Williams and Wilkins(1982).
Barcellini, W., et. al., “Inhibitory Influences of α-MSH peptides on HIV-1 expression in Monocytic cells,” 12thWorld AIDS Conference Geneva, Abstract No. 60685, Jun. 28-Jul. 3, 1998.
Barcellini W, La Maestra L, Clerici G, Garofalo L, Brini AT, Lipton JM, Catania A. α-MSH peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes. Journal of Leukocyte Biology 68:693-699, 2000.
Bhattacharya A., et al., “Effect of Cyclic AMP on RNA and Protein Synthesis inCandida albicans,” Biochem, Biophysics. Res. Commun., 77: 1438-44 (1977).
Bickers, D., Sun-Induced Disorders,Emergency Medicine Clinics of North America,3(4): 659-663, 660 (1985).
Capsoni, F., et. al., “Effect of Corticosteriods on Neutrophil Function: Inhibition of Antibody-dependent Cell-Mediated Cytotoxicity (ADCC),”J. Immunopharmacol. 5, 217-30 (1983).
Cartledge, J.D., et. al., “Clinically Significant Azole Cross-Resistance in Candida Isolates from HIV-Positive Patients with Oral Candidosis,”AIDS11:1839-44 (1997).
Catania, A., et. al., “α-Melanocyte Stimulating Hormone in the Modulation of Host Reactions,”Endocr. Rev. 14, 564-576 (1993).
Catania, A., et. al., “Melanocortin Peptides Inhibit Production of Proinflammatory Cytokines in Blood of HIV-Infected Patients,”Peptides, 19(6): 1099-1104 (1998).
Catania, A., et. al., “The Neuropeptide α-MSH in HIV Infection and Other conditions in Humans,”Ann. N.Y. Acad. Sci. 840: 848-856 (1998).
Catania, A.; et. al., “The Neuropeptide α-MSH has Specific Receptors on Neutrophils and Reduces Chemotaxis in Vitro,”Peptides17, 675-679 (1996).
Catania A, Airaghi L, Lipton JM. α-MSH in normal human physiology and disease states. Trends Endocrinol. Metab. 11:304-308, 2000.
Catania A, Delgado R, Airaghi L, Cutuli M, Garofalo L, Carlin A, Demitri MT, Lipton JM. α-MSH in systemic inflammation: central and peripheral actions. Annals of the New York Academy of Sciences, 885: 183-187, 1999.
Catania A, Grazia M, Manfredi MG, Airaghi L, Ceriani G, Gandino A, Lipton JM. Cytokine antagonists in infectious and inflammatory disorders. Annals of the New York Academy of Sciences 741: 149-161, 1994.
Catania A, Lipton JM. α—melanocyte-stimulating hormone peptides in host responses: from basic evidence to human research. Annals of the New York Academy of Sciences 680: 412-423, 1993.
Catania A, Cutuli M, Garofalo L, Airaghi L, Valenza, F, Lipton JM, Gattinoni L. Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients. Crit. Care Med. 28: 1403-1407, 2000.
Catania A, Airaghi L, Motta P, Manfredi MG, Annoni G, Pettenati C, Brambilla F and Lipton JM. Cytokine antagonists in aged subjects and their relation with cellular immunity. Journal of Gerontology: Biological Sciences 52A: B93-97, 1997.
Catania A, Manfredi MG, Airaghi L, Vivirito MC, Capetti A, Milazzo F, Lipton JM and Zanussi C. Plasma concentration of cytokine antagonists in patients with HIV infection. Neuroimmunomodulation 1: 42-49, 1994.
Catania A, Airaghi L, Manfredi MG, Vivirito MC, Milazzo F, Lipton JM, Zanussi C: Proopiomelanocortin-derived peptides and cytokines: relations in patients with acquired immunodeficiency syndrome. Clinical Immunology and Immunopathology 66: 73-79, 1993.
Cavello, J. and Deleo, V., Sunburn,Dermatologic Clinics, 4(2):181-187, 181 (1986).
Ceriani, G., et. al., “Central Neurogenic Antiinflammatory Action of α-MSH: Modulation of Peripheral Inflammation Induced by Cytokines and other Mediators of Inflammation,”Neuroendocrinology, 59:138-143 (1994).
Ceriani G, Diaz J, Murphree S, Catania A, Lipton JM. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation 1:28-32, 1994.
Chiao H, Foster S, Thomas R, Lipton J, and Star RA. α-MSH reduces endotoxin-induced liver inflammation. J. Clin. Invest. 97: 2038-2044, 1996.
Csata, M. et. al., “Enhancement of Candida albicans killing activity of separated human epidermal cells by alpha-melanocyte stimulating hormone,” British Journal of Dermatology, 121(1) 145-147 (1989).
Cutuli, M. et. al., “Antimicrobial effects of α-MSH peptides,” Journal of Leukocyte Biology 67:233-239 (2000).
Deeter, L.B., et. al., Antipyretic Properties of Centrally Administered α-MSH Fragments in the Rabbit,Peptides 9, 1285-1288 (1989).
Delgado, R., et al., “Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia,”Journal of Leukocyte Biology, 63: 740-745 (1998).
Domk-Optiz, I., et. al., “Stimulation of Macrophages by Endotoxin Results in the Reactivation of a Persistent Herpes Simplex Virus Infection,”Scand J. Immunol. 32(2):69-75 (1990).
Eberle, A. and Schwyzer, R., Hormone-Receptor Interactions,Clinical Endocrinology5, Suppl., 41s-48s (1976).
Eberle, A.N., The Melanotrophins,Karger, Basel, Switzerland(1988).
Fauci, A.S., “Host Factors in the Pathogenesis of HIV-induced Disease,”Nature384: 529 (1996).
Fitzpatrick, et al., Acute Effects of Ultraviolet Radiation on the Skin: The Sunburn Reaction,Dermatology in General Medicine, 4th Edition, 1651-1655, 1651 (1993).
Fitzpatrick, et al., “Color Atlas and Synopsis of Clinical Dermatology,” (1983).
Foster, J. Sunburn
Catania Anna P
Lipton James M
Perkins Coie LLP
Tate Christopher
Teller Roy
Zengen, Inc.
LandOfFree
System and method for support legacy operating system... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System and method for support legacy operating system..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System and method for support legacy operating system... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3641703